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Abstract
Introduction: Fluid strategies may impact on patient outcomes in major elective surgery. We aimed to study the
effectiveness and cost-effectiveness of pre-operative fluid loading in high-risk surgical patients undergoing major
elective surgery.
Methods: This was a pragmatic, non-blinded, multi-centre, randomised, controlled trial. We sought to recruit 128
consecutive high-risk surgical patients undergoing major abdominal surgery. The patients underwent pre-operative
fluid loading with 25 ml/kg of Ringer’s solution in the six hours before surgery. The control group had no pre-
operative fluid loading. The primary outcome was the number of hospital days after surgery with cost-effectiveness
as a secondary outcome.
Results: A total of 111 patients were recruited within the study time frame in agreement with the funder. The
median pre-operative fluid loading volume was 1,875 ml (IQR 1,375 to 2,025) in the fluid group compared to 0
(IQR 0 to 0) in controls with days in hospital after surgery 12.2 (SD 11.5) days compared to 17.4 (SD 20.0) and
an adjusted mean difference of 5.5 days (median 2.2 days; 95% CI -0.44 to 11.44; P = 0.07). There was a
reduction in adverse events in the fluid intervention group (P = 0.048) and no increase in fluid based
complications. The intervention was less costly and more effective (adjusted average cost saving: £2,047;
adjusted average gain in benefit: 0.0431 quality adjusted life year (QALY)) and has a high probability of being
cost-effective.
Conclusions: Pre-operative intravenous fluid loading leads to a non-significant reduction in hospital length of stay
after high-risk major surgery and is likely to be cost-effective. Confirmatory work is required to determine whether
these effects are reproducible, and to confirm whether this simple intervention could allow more cost-effective
delivery of care.
Trial registration: Prospective Clinical Trials, ISRCTN32188676
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High-risk patients undergoing major surgery are at sig-
nificant risk of death or major morbidity [1,2]. One of
the largest bodies of evidence in this field is around
“pre-operative optimisation” in major high risk surgery
[3-5]. This label characterises a highly complex interven-
tion which comprises a raft of intervention components.
These include: pre- and post-operative admission to an
ICU; pre-operative placement and monitoring with a
pulmonary artery catheter; pre-operative intravenous
fluid loading followed by inotropic support to achieve
and maintain supranormal cardiac indices and oxygen
delivery targets [3-7]. Randomised studies have sug-
gested a significant outcome advantage from this strat-
egy [3-6]. In this group, meta-analysis of randomised
controlled trials suggests that pre-operative optimisation
improves morbidity and mortality as well as reduces
hospital length of stay [7].
However, despite this evidence base, pre-operative
optimisation has failed to have significant penetration
into clinical practice with apparent low levels of imple-
mentation in most countries. Reasons for this failure to
implement are unclear but lack of ICU beds for patients
prior to surgery may be a major factor in some coun-
tries [8]. This inability to implement this intervention
may, at least in part, have led to a move towards peri-
operative and post-operative optimisation strategies
[9-14].
These strategies also aim to target goals for cardiac
index and oxygen delivery using a variety of fluid and
inotropic interventions targeted via a range of cardiac
output monitoring devices [9-14]. There is evidence that
a variety of these optimisation strategies may be of bene-
fit in terms of hospital length of stay but there is a lack of
evidence for important improvements in mortality or on
the cost-effectiveness of care. A further reason clinical
teams may not have implemented these strategies
includes the growing data on fluid restrictive strategies in
major surgery [15-18]. This literature supplies evidence
that peri-operative restriction of fluid may improve out-
come from major surgery. This evidence, at least superfi-
cially, seems contradictory to the pre-operative
optimisation evidence and this has split opinions on the
optimal peri-operative fluid management strategy [19].
It is unclear from this evidence base whether the ben-
efit from these interventions can be attributed to the
entire intervention package or whether the benefits can
be obtained from individual or combined components
of these interventions. We hypothesised that fluid load-
ing would be associated with benefit in high-risk surgi-
cal patients. We aimed to test whether ward-based pre-
operative fluid loading cost-effectively shortened hospital
length of stay in high-risk surgical patients undergoing
major elective surgery.
Materials and methods
This was a multi-centre, prospective, randomised, con-
trolled trial conducted in four Scottish hospitals, coordi-
nated from the Centre for Healthcare Randomised
Trials in the Health Services Research Unit, University
of Aberdeen [20]. The trial was designed as a partial 2*2
factorial design with initial randomisation to fluid load-
ing versus no fluid loading, with a secondary randomisa-
tion (if an ICU bed was available at the time of
recruitment) to intensive care (level 3) versus high
dependency (level 2) care [20]. The second randomisa-
tion had to be abandoned, however, due to a continuing
lack of ICU beds at the time of patient recruitment (this
decision was agreed upon with the funder, the Data
Monitoring Committee (DMC) and the Trial Safety
Committee (TSC). As such, this paper presents the
results for the single comparison of fluid loading versus
no fluid loading. The design features and estimates used
in this protocol were informed by the results of a 15-
week pilot program undertaken in the Aberdeen Royal
Infirmary during which 23 patients were recruited (not
included in this analysis). The main study was underta-
ken in three university hospitals (Aberdeen Royal
Infirmary, Glasgow Royal Infirmary and Glasgow Wes-
tern Infirmary) and one distric tg e n e r a lh o s p i t a l( R o y a l
Alexandra Hospital, Paisley).
Participants were recruited from the elective operating
schedules in the recruiting hospitals and informed con-
sent was obtained. Patients were, in general, identified
following a pre-assessment visit at a local hospital or
following their initial appointment with the surgeon.
They were sent an information leaflet prior to their hos-
pital admission whenever possible. Informed consent
was sought from these patients on their admission to
hospital. Patients were fasted according to local hospital
fasting policies and always for at least six hours before
surgery. No hospital in the study allowed consumption
of carbohydrate rich fluids up to two hours before
surgery.
Inclusion criteria included patients undergoing major
elective intra-abdominal surgery including major intra-
peritoneal surgery, major open aortic surgery, major
renal and bladder surgery and hysterectomy and
oophorectomy for cancer. Patients were required to fulfil
two high-risk surgical criteria according to the Revised
Cardiac Risk Index (RCRI); these include a high risk
type of surgery, presence of ischaemic heart disease, his-
tory of congestive heart failure, history of cerebrovascu-
lar disease, insulin therapy for diabetes and pre-
operative serum creatinine > 160 μmol/L [21]. Patients
who underwent open or laparoscopically-assisted sur-
gery were eligible. Clinical exclusion criteria included
clinician concern about the safety of interventions, New
York Heart Association grade IV heart failure,
Cuthbertson et al. Critical Care 2011, 15:R296
http://ccforum.com/content/15/6/R296
Page 2 of 12emergency surgery, chronic renal failure/creatinine >
300 μmol/L, lack of informed consent, age < 16 years,
pregnancy, major hepatic surgery, and expected survival
< 6 months.
Participants were randomised through an interactive
voice response automated telephone randomisation ser-
vice on the day before surgery. A minimisation algo-
rithm was used, incorporating centre, age, sex and type
of surgery [22]. POSSUM (Pre-Operative and Operative
Physiological and Operative Severity Score for Enumera-
tion of Mortality and Morbidity) scores were measured
to derive physiological disturbance and operative sever-
ity [23].
Fluid interventions
Patients were randomised to ward-based intravenous
pre-operative fluid loading or no pre-operative fluid
loading. The pre-operative fluid loading group patients
were electively commenced on 25 ml/kg Ringer’sl a c t a t e
solution over the six-hour period in the ward setting
before surgery [5]. In the standard fluid regimen no rou-
tine pre-operative fluid loading was given. All patients
receiving bowel preparation were given 10 ml/kg Ring-
er’s lactate solution in the 12- to 6-hour period before
surgery irrespective of trial group allocation as this is
deemed to be the best clinical practice. Fluids were not
warmed during administration. This meant that fluid
loading patients who received bowel preparation would
receive 35 ml/kg in the 12 hours before surgery.
All non-protocol fluid prescriptions and other man-
agement decisions were made by the clinically responsi-
ble surgical team. We did not control or protocolise the
time of discharge from hospital. Due to the nature of
the interventions no blinding of the interventions was
possible.
All participants were followed up daily for one week
for major morbidity and mortality, then at hospital dis-
charge and then one, three and six months after surgery
for survival and quality of life. The decision to discharge
t h ep a t i e n tf r o mh o s p i t a lw a sm a d eb yt h ec a r i n gt e a m
with no involvement of the study personnel. Study out-
comes measured during hospital stay were measured by
study personnel not blinded to the intervention. Out-
comes assessed after hospital discharge were measured
using postal participant questionnaires.
Outcomes
The primary outcome was the number of days in hospi-
tal after surgery [9-13] Secondary outcomes included
cost-effectiveness at six months, measured by the Net
Benefit statistic, which is calculated using the following
equation: ((l * quality adjusted life year (QALY)) -
costs) where l indicates society’s ‘willingness to pay’ (l
is typically set at £20,000) [24], QALY are calculated
using EQ-5D scores and costs included both primary
and secondary care costs [25]. Other secondary out-
comes, including measures of health status, included
changes in health status and quality of life over 6
months after surgery and quality of life at 48 hours, 1, 3
and 6 months after surgery, measured using SF-36 and
EQ-5D [25-27]; health care costs including full hospital
costs and primary care costs; mortality measured using
time-to-event analysis; and the level of major morbid-
ities in hospital using the Post-Operative Morbidity Sur-
vey at days 1, 3 and 7 after surgery (POMS) [28] Serious
adverse events were assessed by clinical leads defined
according to standard definitions, (that is, an untoward
occurrence that results in death, is life-threatening,
requires hospitalisation or prolongation of existing hos-
pitalisation, results in persistent or significant disability
or incapacity, consists of a congenital anomaly or birth
defect, or is otherwise considered medically significant
by the investigator) [29].
Sample size
The full power calculation is presented in the trial pro-
tocol paper [20]. For the fluid comparison, we aimed to
be able to detect a 0.5 SD difference in the primary out-
come of number of days in hospital following surgery,
with 80% power and 5% significance. This resulted in a
target sample size of 128 patients. Data on number of
days in hospital were available for all patients in the
trial.
Statistical analysis
The statistical analysis was based on all people rando-
mised, irrespective of subsequent compliance to treat-
ment allocation. Trial analysis was undertaken using
standard methods for two-group comparisons for con-
tinuous, binary and time-to-event outcomes using inten-
tion to treat principles. All statistical analyses were pre-
specified in a Statistical Analysis Plan which was agreed
upon before the analysis was undertaken. The primary
analysis was adjusted for the minimisation variables
using analysis of covariance. A significance level of P <
0.05 was considered as evidence of statistical significance
for the primary outcome and confidence intervals pre-
sented. An ap r i o r isecondary subgroup analysis was
investigated through tests for interaction and included
patients with high cardiac risk [21]; patients with high-
grade functional limitation due to heart failure and type
of surgery. Stricter levels of statistical significance (P <
0.01) were sought, reflecting the exploratory nature of
these subgroup analyses.
Economic analysis
A within trial economic analysis was conducted from
the UK National Health Services’ perspective.
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six months. Benefits in thee c o n o m i ca n a l y s i sw e r e
reported in terms of QALYs estimated from the
responses to the EQ-5D questionnaire at five time
points - baseline (before surgery), 48 hours, 1 month, 3
months and 6 months after surgery. These responses
were converted to utility values using the EQ-5D social
tariff, which has been estimated from a representative
sample of the UK population [25]. The utility scores
obtained at these time points were transformed into
QALYs using the area under the curve method by
assuming linear extrapolation between subsequent data
collection time points.
Patient specific data for the use of NHS resources
were retrieved using patient case notes (post-operative
inpatient length of stay and outpatient visits) as well as
six months’ questionnaires to participants (primary care
contacts and medicines consumed). Unit costs were
retrieved from a number of publicly available sources
[30-32]. Intervention cost for base case analysis consid-
ered no extra time for pre-operative fluid loading, 30
minutes doctor’s time and 42 minutes nurse’s time.
Sensitivity analyses were performed for cost and
QALYs by alternatively excluding from the analysis par-
ticipants with 5% and 10% highest and lowest total cost
or QALYs. Moreover, the intervention cost was adjusted
by adding 12 hours inpatient time in the surgical ward.
This scenario would be relevant if normal practice (in
the absence of fluid loading) was to conduct surgery on
the day of admission. In this situation, patients who
receive the fluid intervention would be required to be
admitted to hospital earlier to allow time for pre-opera-
tive fluid loading to take place. Furthermore, alternative
bed-ridden EQ-5D scores were used as baseline utility
scores for all participants (that is, -0.402). Finally, miss-
ing data were not regarded ap r i o r ias an issue for the
base case analysis. However, this was tested by imputing
mean EQ-5D and mean costs for those categories with
missing data within each study group and this was
further explored using multiple imputation techniques.
A base case analysis and sensitivity analyses were per-
formed. For every analysis, differences in mean total
cost and mean QALY data were bootstrapped (1,000
repetitions) adjusting for minimisation variables as well
as baseline EQ-5D score [33].
Trial oversight
The Multicentre Research Ethics Committee for Scot-
land approved the study (Ref 04/MRE10/76). The trial
was registered in a public trials registry (registry number
ISRCTN32188676). The trial was overseen by a TSC
with an independent Chair and an independent DMC
reviewed accruing data at regular intervals.
Role of the funding source
The study sponsor and funding source had no role in
the collection, analysis and interpretation of data, or in
the writing of the report, or in the decision to submit
the paper for publication.
Results
The study recruited from 1 September 2007 until 4 May
2009. During the study timeframe agreed upon with the
funder, a total of 274 patients were deemed eligible for
the trial, of whom 111 were recruited. Figure 1 presents
the Consolidated Standards on Reporting Trials (CON-
SORT) diagram and reasons for trial exclusion (163
were excluded for clinical reasons, were missed or did
not consent). Of the 111 patients recruited, 57 were ran-
domised to fluid loading and 54 participants to the fluid
control group. Further details of the patients’ surgical
procedures are presented in Additional file 1. In the
fluid loading group, one patient withdrew after randomi-
sation but before surgery and a second patient was
excluded post-randomisation for clinical reasons (before
surgery). All others patients remained in the study until
the primary outcome time point. Lost to follow-up for
secondary outcomes at six months were four (7%)
patients in the fluid loading group and zero (0%)
patients in the fluid control group. (These were the two
withdrawn before surgery and a further two patients
who declined further follow-up at six months). Baseline
characteristics are shown in Table 1 and surgical proce-
dures are presented in the Additional file 1.
The study interventions and clinical management
received in the pre-operative, intra-operative and post-
operative periods are presented in Table 2. This table
demonstrates the median pre-operative fluid loading
volume was 1,875 ml (IQR 1,375 to 2,025) in the fluid
loading group compared to 0 (IQR 0 to 0) in the fluid
control group. It also demonstrates the median total
pre-operative fluid was 1,975 ml (IQR 1,500 to 2,275) in
the fluid loading group compared to 0 (IQR 0 to 721) in
the fluid control group. The difference between these
numbers within the groups was due to pre-operative IV
fluid given to replace presumed fluid losses due to oral
bowel preparation in line with the protocol. Table 2 also
demonstrates that the total IV fluid given in the com-
bined pre and intra-operative periods combined was
4,186 ml (IQR 3,500 to 5,527) in the fluid loading group
versus 3,000 ml (IQR 2,500 to 4,050) in the fluid control
group. Table 2 also gives details of the time spent in
high dependency care or intensive care for each group
(treatment received). The mean (SD) preoperative systo-
lic arterial pressure (SAP) was 135 (SD 19) in the fluid
loading group and 134 (SD 23) in the controls (P =
0.782). Immediately after induction of anaesthesia SAP
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Figure 1 CONSORT diagram of patient recruitment and retention in the study until final follow-up at six months. Clinical exclusions:
failed to meet inclusion critieria = 13 (emergency surgery (8), inadequate time to deliver intervention (3), not high-risk surgery (2). Presence of
exclusion criteria 24 (unspecified clinician concern (8), NYHA grade IV (1), chronic renal failure/creatinine > 300 umol.L
-1 (9), unstable angina (1),
planned elective admission to ICU (4), surgery scheduled after completion of recruitment (1)).
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Page 5 of 12was 112 (25) in the fluid loading group and 106 (24) in
the controls (P = 0.386).
There were no serious adverse events leading to per-
sistent or significant disability or incapacity in either
group. Serious adverse events prolonging hospital stay
were seen in 6 (11%) patients in the fluid loading group
a n d1 4( 2 6 % )p a t i e n t si nt h ef l u i dc o n t r o lg r o u p( P =
0.048). Of these, six were life threatening with two (4%)
patients in the fluid loading group and three (6%)
patients in the fluid control group (P = 0.673). The
adverse events were cardiac (2 in the fluid group, 1 in
the control group), arrhythmias (1 vs 0), gastrointestinal
(2 vs 5), infectious (1 vs 5), other (0 vs 1). More details
are presented in Additional file 2.
Table 3 demonstrates the primary trial outcome of
days in hospital after surgery. This table demonstrates a
mean hospital stay of 12.2 (SD 11.5) days in the fluid
loading group compared to 17.4 (SD 20.0) in the fluid
control group with an adjusted mean difference of 5.5
days (median 2.2 days; bootstrapped 95% CI -0.44 to
11.44; P = 0.07). Similar effect sizes are seen for hospital
admission until hospital discharge (mean difference:
5.99; CI -0.19 to 12.18) and for days from randomisation
until hospital discharge (mean difference: 9.03; CI 0.96
to 17.11).
Table 4 demonstrates secondary outcomes including
post-operative morbidity measured using the POMS
score [28] at one, three and seven days and operative
morbidity measured using the operative POSSUM score
[23] and crude mortality at hospital discharge, three
months and six months. No patients required mechani-
cal ventilation after surgery, with all patients being extu-
bated in the operating room immediately after surgery.
Table 5 shows cost effectiveness results for the base
case analysis. Pre-operative fluid loading on average
costs less (£10,373) than standard care (£11,739) with an
adjusted mean difference of -£2,047 (bootstrapped 95%
CI: -£6,947 to £2,854; P = 0.413). Moreover, pre-
Table 1 Baseline characteristics of the study groups
Fluid loading (n = 57) Fluid control (n = 54)
Age - median (IQR) years 69 (64, 78) 73 (64, 80)
Sex - n (%) male 41 (72%) 38 (70%)
Surgical group - n (%)
Abdominal with bowel preparation 22 (39%) 26 (48%)
Abdominal without bowel preparation 19 (33%) 17 (31%)
Urological/Gynaecological 8 (14%) 4 (8%)
Vascular 8 (14%) 7 (13%)
Operative approach - n (%)
Open surgery 47 (85%) 38 (70%)
Laparoscopic surgery 6 (11%) 13 (24%)
Not recorded 2 (4%) 3 (6%)
Analgesia - n (%)
Epidural analgesia 39 (71%) 36 (67%)
Patient controlled analgesia (PCA) 15 (27%) 17 (31%)
Combined epidural + PCA 1 (2%) 1 (2%)
Central venous line monitoring 42 (76%) 38 (70%)
Arterial monitoring 41 (75%) 46 (85%)
Pre-operative ASA Grade - n (%)
2 25 (44%) 22 (41%)
3 30 (53%) 31 (57%)
4 2 (4%) 1 (2%)
Pre-operative physiological POSSUM score - median (IQR) 21 (16, 24) 23 (19, 26)
Revised Cardiac Risk Index
6- n (%)
2 52 (91%) 45 (83%)
> 2 5 (9%) 9 (17%)
NYHA - n (%)
0 to 1 29 (51%) 31 (57%)
2 to 3 27 (47%) 23 (43%)
Missing 1 (2%) 0 (0%)
ASA, American Society of Anaesthesiologists; IQR, Interquartile range; n, number; NYHA, New York Heart Association; POSSUM, Physiologic and Operative Severity
Score for the enUmeration of Mortality and Morbidity.
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(QALY = 0.3527) than no fluid loading (QALY = 0.3175)
with an adjusted mean difference of 0.0431 (bootstrapped
95% CI: -0.0171 to 0.1033; P = 0.161); this difference
being equivalent to about 7.87 days over a 6-month trial
follow-up period. Table 5 illustrates a high probability
that the intervention is dominant compared with a no
fluid loading approach. The CEAC shows that there is a
high probability that the intervention will be cost-effec-
tive at all the threshold values of willingness to pay for a
QALY presented (table 5).
Sensitivity analyses were conducted on both the cost
and QALY calculations (data not shown). The fluid
intervention remains dominant (less costly and more
effective) for all but one of the sensitivity analyses con-
sidered. In this analysis, we trimmed the 5% most costly
data from the no fluid arm of the trial. In this case, the
intervention was more costly and more effective,
reflected in an incremental cost-effectiveness ratio
(ICER) of £24,810 per QALY gained. This analysis
represents a worst case scenario, in which fluid loading
is still cost effective as the ICER is less than the £30,000
Table 2 Study interventions and clinical management received in the pre-operative, intra-operative and post-
operative periods
Fluid loading (n = 57) Fluid control (n = 54)
Median (IQR) Min, Max Median (IQR) Min, Max P-value
Pre-operative fluid load* (ml) 1,875
(1,375, 2,025)
0, 2,950 0
(0, 0)
0, 1,415 < 0.001
Additional IV fluid load in: bowel preparation 00
patients (ml) (0, 0) 0, 1,475 (0, 693) 0, 1,500 0.397
Total pre-operative fluid (ml) 1,975
(1,500, 2,275)
0, 4,130 0
(0, 721)
0, 1,500 0.000
Intra-operative fluid (ml) 2,200
(1,738, 3,500)
970, 7,000 3,000
(2,075, 3,808)
1,000, 6,685 0.078
Total pre and intra-operative fluid (ml) 4,186
(3,500, 5,527)
2,000, 9,543 3,000
(2,500, 4,050)
1,000, 7,885 < 0.001
Total fluid in 24
hours after surgery (ml)
3,512
(2,975, 4,356)
1,064, 5,900 3,770
(3,084, 4,434)
1,875, 6,644 0.307
Total fluid between 24
and 48 hours after surgery (ml)
3,000
(2,340, 3,416)
1,320, 6,348 3,219
(2,484, 3,942)
1,650, 4,850 0.235
Initial post-operative care location (treatment delivered) n (%) n (%)
ICU care 14 (25%) 7 (13%)
HDU care 35 (64%) 46 (85%)
Ward care 6 (11%) 1 (2%)
Median (IQR) Min, Max Median (IQR) Min, Max P-value
Total time in ICU after
surgery (hrs)
0
(0, 7.2)
0, 701.2 0
(0, 0)
0, 331.0 0.327
Total time in HDU after
surgery (hrs)
71.5
(44.0, 120.2)
0, 580.3 92.9
(67.4, 148.2)
0, 617.4 0.028
Total time in Ward after surgery (hrs) 122.5
(89.3, 216.5)
22.3, 1198.5 164.5
(90.9, 303.8)
5.0, 3080.0 0.204
Hrs, hours; IQR, Interquartile range; ml: millilitres.
*Two participants in the fluid loading group were treated as part of the trial but received no pre-operative fluid loading and four participants in the fluid control
group received pre-operative fluid loading.
Table 3 The primary trial outcome of days in hospital after surgery
Fluid
loading (n = 55)
Fluid
control
(n = 54)
Effect size Bootstrap
95% CI
P-value
Days in hospital after surgery
mean (SD) 12.2 (11.5) 17.4 (20.0) 5.50 -0.44, 11.44 0.070
median (IQR) 8.8
(6.9,13.0)
11.0
(7.8, 18.9)
2.2
CI, confidence interval; IQR, interquartile range; SD, standard deviation.
The effect size is the difference in means adjusted for minimisation covariates.
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National Institute of Health and Clinical Excellence
(NICE). These would, however, reflect clinically impor-
tant patients, and their exclusion from the analysis may
not be a correct representation of the population being
studied. Nonetheless, in this one analysis fluid loading
was associated with an ICER of less than £30,000, a
value commonly adopted by NICE for technology
appraisal. Conclusions remained unaltered for the “day
of surgery admission” sensitivity analysis. This further
highlights the high likelihood of cost-effectiveness of the
interventions across a variety of assumptions.
Subgroup analysis of the effects of cardiac risk, heart
failure grade and type of surgery showed no evidence of
interaction with the main effect of the intervention (data
not shown).
Discussion
The study demonstrated a non-significant trend towards
a reduction of hospital length of stay with a mean differ-
ence of 5.50 (-0.44, 11.44) days (median 2.20 days). This
direction of effect was also observed when considering
total duration of hospital stay and days from study
randomisation until hospital discharge. Observed differ-
ences towards improvements in secondary outcome
measures also support the proposition that fluid loading
is likely to be beneficial by showing that pre-operative
fluid loading tended towards reduced serious adverse
events that prolonged hospital stay and resulted in a
non-significant reduction in post-operative morbidity (at
seven days). The finding of the economic analysis was
that fluid loading results in, on average, lower costs and
greater benefits than no fluid loading. Cost savings asso-
ciated with the intervention were mainly driven by
longer post-operative inpatient length of stay in the
fluid control group (data not shown). Based on the bal-
ance of probabilities; there is a high probability that
fluid loading is cost-effective compared to fluid control.
The fluid intervention
The fluid loading group received a median of 1,875 ml
of Ringer’s solution in the pre-operative period com-
pared to a median of 0 ml in the control; this correlates
well with the 25 ml/kg protocolised target pre-operative
fluid load. This fluid was delivered over a six-hour per-
iod before surgery. With clinical practice changing
Table 4 Trial secondary outcomes
Fluid loading Fluid control Odds ratio† 95% CI P-value
Operative POSSUM score - median (IQR) 12 (9,16) 12 (9,16) na* na na
POMS outcomes
Day 1 POMS morbidity 55 (100%) 53 (98%) na** na na
- Day 3 POMS morbidity 52 (94%) 50 (93%) 1.604 0.277 to 9.279 0.598
- Day 7 POMS morbidity*** 23 (51%) 31 (67%) 0.515*** 0.200 to 1.326 0.169
Hospital mortality 1 (2%) 1 (2%) 0.981 0.012 to 78.476 1.000
3-month mortality 1 (2%) 3 (6%) 0.315 0.006 to 4.106 0.994
6-month mortality 1 (2%) 4 (8%) 0.231 0.005 to 2.471 0.995
CI,: confidence interval; IQR, Interquartile range; POMS, post-operative morbidity score; POSSUM, Physiologic and Operative Severity Score for the enUmeration of
Mortality and Morbidity.
* statistical significance not tested due to small number of events. ** 100% incidence in fluid group makes testing inappropriate. *** 19 participants (10 in fluid
group and 9 in non-fluid group) were discharged less six days after surgery.
†Odds ratios adjusted for minimisation covariates. Post-operative morbidity measured using POMS
28 on days 1, 3 and 7 and operative complexity measured
using operative POSSUM score
23 and crude mortality at hospital discharge, 3 months and 6 months.
Table 5 The base case economic evaluation results
Base case ICER calculations Threshold analysis*: probability of
cost-effective at alternative values
of willingness to pay for a QALY
(%)
Mean total
cost (£)
Incremental cost (£) Mean
QALY
Incremental QALY ICER
(£/QALY)
£10,
000
£20,
000
£30,
000
£50,
000
Fluid loading 10,373 0.3527 84.4 86.5 89.4 92.0
Fluid control 11,739 -1,366 0.3175 0.0352 Dominated 15.6 13.5 10.6 8.0
Adjusted
differences
(95% CI; P-value)
*
-2,047
(-6,947 to 2,854; P =
0.413)
0.0431
(-0.0171 to 0.1033; P =
0.161)
CI, confidence interval; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year.
* Adjusted for minimisation variables and baseline EQ-5D score and based on 1,000 bootstrap iterations.
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Page 8 of 12towards day of surgery admission in many countries,
future studies in this area may find it difficult to deliver
this intervention and may choose to consider testing
whether shorter periods of fluid administration are
appropriate; for instance, delivery of the fluid interven-
tion in a two-hour period rather than six. It is important
to identify that our sensitivity analysis suggests that the
intervention is still highly likely to be cost-effective even
if patients, who would normally be admitted on the day
of surgery, had to be admitted to hospital up to 12
hours earlier (that is, the night before surgery) to receive
the intervention.
W i t hr e g a r dt ot h ec h o i c eo ff l u i du s e d ,w ec h o s e
Ringer’s solution due to our desire to select a crystalloid
and use a balanced solution. We believe this was the
appropriate choice and would be unlikely to change this
selection in a future study. In this study we specifically
documented cardiac adverse events as being potentially
important morbidities related to the fluid intervention
but there was no evidence of increased cardiac adverse
events associated with fluid loading and, indeed, there
w a sar e d u c t i o ni no v e r a l la d v e r s ee v e n t si nt h ef l u i d
group. We do not have direct data to explain why there
were fewer gastro-intestinal and infectious adverse
events in the fluid group but this may be explained by
an improvement in cardiac output and oxygen delivery
that would be expected in patients having fluid loading
[3-7]. This may improve tissue (including gut blood
flow) and reduce anastomotic breakdown and reduce
tissue infection. Some centres use cardiac output guided
therapy to guide fluid therapy in such patients and it
will be important to test this fluid intervention com-
bined with, or compared to such peri-operative strate-
gies. Despite the lack of clinical evidence of fluid related
complications in this study the use of more invasive
monitoring in future studies may allow a more full
investigation of this issue.
What this study adds
We hypothesised that simple pre-operative fluid loading
would represent a straightforward and cost-effective way
to shorten stay and improve outcome after major high
risk surgery. We designed the intervention to be as sim-
p l ea n dp r a g m a t i ca sp o s s i b l eb yd e l i v e r i n gaf i x e d
“dose” ( 2 5m l / k g )o fi n t r a v e n o u sR i n g e r ’s lactate solu-
tion in the six hours before surgery in the ward environ-
ment without the requirement to site, monitor or target
the complex cardiovascular targets that cardiac output
devices allow. This intervention was designed to be
easily protocolized for clinical practice and be delivered
by non-medical staff to further enhance its utility.
We have demonstrated a trend towards a reduction in
hospital length of stay after surgery and that the fluid
intervention is likely to be cost-effective. This is
supported by concomitant observed reductions across
both the high dependency and ward length of stay, both
of which are reduced in the fluid loading group. We
also demonstrated that fluid loading was associated with
short term reductions in adverse events as well as
improvements in longer term (six-month) outcomes,
such as the effectiveness of care, reductions in health
care costs and improved cost-effectiveness as well. All
these secondary outcomes show effects in the direction
of benefit for the intervention and help us understand
the contributing factors that are associated with
improvements in outcome.
The mechanisms by which this fluid intervention
appears to reduce hospital length of stay are not entirely
clear from the results of the study. We know that the
fluid loading group received the pre-operative fluid
intervention as per protocol and received a significantly
greater amount of fluid before surgery commenced. This
group was also found to have received more fluid by the
end of surgery than the fluid control group. Therefore,
these patients received more fluid, earlier, than controls
and much of this fluid was administered before the sur-
gical insult. Pre-operative optimisation studies often
demonstrate an increase in cardiac index and oxygen
delivery with fluid loading alone, which is further aug-
mented by inotropic support to achieve supranormal
oxygen delivery targets [3-7]. We would hypothesis that
pre-operative fluid loading improves cardiac output and
oxygen delivery, but to levels below “supranormal” levels
[3,5,34], and this is associated with improved organ per-
fusion and function [3,5,34], fewer surgical complica-
tions [35] and fewer adverse events, lower post-
operative morbidity, and these factors contribute to the
shorter length of stay in hospital after surgery. The mag-
nitude of reduction in hospital length of stay is similar
to that seen in other optimisation studies [5,9-11]. It
should be noted that this study, and the pre-optimisa-
tion literature, appears to contradict the evidence base
for intra-operative fluid restriction, which has appeared
more recently [15-19]. However, the apparent discre-
pancy between these two bodies of evidence may be less
difficult to reconcile than it appears. There are seven
randomised studies in the literature on fluid restriction
and of these only three show benefit [36]. Evidence
from the first study of fluid restriction strategies sug-
gests that restricting day of surgery fluid intake from
approximately 6,200 ml (of which 5,388 ml were IV) to
approximately 3,700 ml (of which 2,740 ml were IV)
may be beneficial in terms of complications [15].
Whereas, the current study, and many of the studies
cited in the pre-operative optimisation literature, utilise
peri-operative fluid loads of 3,000 to 4,000 ml [5]. In
studies of fluid restriction, a range of a “liberal intra-
operative fluid regimens” from 2,750 to 5,388 ml
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Page 9 of 12compared with 998 to 2,740 ml for the “restrictive fluid
regimen”[36]. This may suggest that “restrictive fluid
regimens” may not actually differ that significantly from
optimization strategies in terms of fluid volume. The
difference that may explain these two apparently contra-
dictory strategies may relate to either the timing of the
fluid administration (early preoperative fluid loading
being beneficial and late post-operative fluid overloading
being harmful) or related to the achievement of “supra-
normal” targets. In the Noblett study, which utilised an
intra-operative fluid optimisation regime, a significant
majority of the fluid administration occurred in the first
40 minutes of surgery [9]. Therefore, there could be an
argument that we should target early (pre- and early
intra-operative) fluid loading/optimisation and then
move to target late (end of surgery) active fluid restric-
tion to avoid post-operative fluid overload and late com-
plications. These bodies of evidence may, therefore, be
complementary and not contradictory [37].
If this reduction in hospital length of stay can be repli-
cated in a larger study then this finding will have a
major impact on service delivery and resource alloca-
tion. From a patient’s perspective this could allow them
to get back to their home environment earlier. The
intervention may also lead to less adverse events and
other acute morbidities, which would clearly have direct
patient benefit. From a clinical practice perspective, this
intervention would be simple, inexpensive and is likely
to be cost-effective as well as being relatively easy to
implement in acute hospitals. There would be little edu-
cational support required for implementation as the
knowledge and skills are already present in surgical
teams in all acute hospitals. The intervention could be
easily protocolized and nurse-led to allow reliable and
reproducible delivery in practice. This reduction in
length of stay would lead to significant direct savings in
clinical budgets and allow the re-allocation of these
resources. The simplicity and low cost of this interven-
tion may make it more attractive than other optimisa-
tion strategies [3-14].
Strengths and weaknesses
One of the main strengths of this trial is the importance
and simplicity of the clinical research question. We
believe this is the first randomised controlled trial of
fluid loading in high risk major surgery. The multi-cen-
tre nature of the study adds to the generalizability of the
study results. The simplicity and low cost of the fluid
intervention are key factors making this intervention
comparatively simple to implement into surgical practice
internationally. An integral part of the study was a pro-
spective cost-effectiveness analysis that is unique in this
clinical field and still uncommon in randomised clinical
trials in acute care. The economic evaluation has been
conducted using the best available methods, including
an extensive and detailed costing approach. This analysis
suggests that the fluid loading intervention is highly
likely to be cost-effective, adding greatly to the impor-
tance and impact of the study. However, this study was
not powered to detect a difference in cost-effectiveness
between groups. Therefore, it is perhaps not surprising
that the evidence on cost-effectiveness falls short of con-
ventional levels of statistical significance. Consideration
has, therefore, been given to the balance of probabilities
when drawing conclusions about cost-effectiveness.
There was some minor imbalance between groups with
regard to baseline characteristics, such as age and num-
ber of patients undergoing abdominal surgery with
bowel preparation. A slightly higher number of patients
in the fluid intervention group received ICU care in the
early post-operative period and this could be argued to
introduce a bias in favour of the intervention group by
improving the care delivered to this group. This differ-
ence is believed to have occurred by chance and not be
driven by clinical issues, including no increase in the
requirement for post-operative ventilation and no major
differences in surgery performed. The definition of high
risk status varies between studies and we chose to use
one of the most widely used RCRI [21]. Despite the pre-
cise application of this score we still recruited patients
with American Society of Anesthesiologists (ASA)
grades of 2 and, therefore, apparent low to moderate
risk patients. This does not represent a misclassification
of patients but does mean the study group is moderate
to high risk by some clinical risk criteria. We believe the
external generalizability of this study is high. Such high
risk patients undergo major surgery in all countries and
they have a significant morbidity and mortality. This
intervention is applicable and implementable in all
developed countries but many countries have day of sur-
gery admission. Since the loading dose of fluid is rela-
tively modest, it does not seem unreasonable to think
this intervention could be delivered in the two to three
hours before surgery for patients admitted on the day of
surgery. Further, our sensitivity analysis suggests that it
would still be highly likely to be cost-effective to admit
such patients up to 12 hours before surgery (the night
before) to receive their fluid intervention. Our median
total length of stay for this surgery seems to be broadly
in line with UK averages and other studies [14,38],
although above those lengths of stays seen in “fast track
surgery studies” [15,18,36]. A further significant weak-
ness was that our final recruitment total was short of
our desired sample size (111 instead of 128), which
meant that we were slightly underpowered to detect our
ap r i o r iproposed minimally important difference of 0.5
SD (111 patients gave 80% power to detect 0.54 SD
change rather than 0.5 SD).
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We conclude that, when applied to high-risk major sur-
gery patients, pre-operative intravenous fluid loading with
25 ml/kg Ringer’s lactate solution may lead to a clinically
important reduction in hospital length of stay after sur-
gery. Further, pre-operative fluid loading is likely to be
cost-effective. Further confirmatory work is required to
determine whether this effect is important and reproduci-
ble. We suggest that this be conducted in the form of a
multi-centre, randomised, controlled trial of pre-operative
fluid loading in high-risk major surgery with the power to
test the effects of the intervention on hospital morbidity
and mortality, and hospital length of stay, as well as cost-
effectiveness of care. If these results are confirmed, then
this simple intervention can allow more effective and less
expensive delivery of surgical services.
Key messages
￿ Fluid optimisation around the time of major sur-
gery is a controversial issue with evidence supporting
pre-optimisation and supranormalisation and also
favouring fluid restriction.
￿ O n eo ft h ek e ye l e m e n t so f pre-optimisation is
fluid loading before surgery. There is little evidence
to guide practice on the role of simple fluid loading
alone in preparation for surgery.
￿ W ep e r f o r m e da nR C To ff l u i dl o a d i n gb e f o r e
major surgery and have demonstrated that there is a
potential for benefit in terms of hospital stay and
cost-effectiveness for this therapy.
￿ Further studies are required to corroborate these
results.
Additional material
Additional file 1: Surgical procedure for trial participants by
minimisation group.
Additional file 2: The effect of adverse events and on length of stay
according to surgical procedure.
Additional file 3: FOCCUS collaborators’ group.
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